AUTHOREA
Log in
Sign Up
Browse Preprints
LOG IN
SIGN UP
All Authorea-powered sites will be offline 6am-10am EDT Tuesday 11 June
for
Essential Maintenance
. We apologise for any inconvenience.
Ruth Maria Urbantat
Member of:
Charité – Universitätsmedizin Berlin
Public Documents
1
CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukaemia – a case report
Ruth-Maria Urbantat
and 8 more
July 30, 2020
CPX-351 is a promising new therapeutic option for patients with treatment related (tAML) or secondary acute myeloid leukemia (sAML). It exceeded classic 7+3 therapy in overall survival (OS) and complete remission rates (CR) while providing a similar risk profile. Until now, this sub-group of AML patients had a worse overall